Objective: Memantine, an uncompetitive N-methyl-daspartate receptor antagonist, is currently approved by the US Food and Drug Administration for the treatment of moderate to severe Alzheimer's disease. Anecdotal reports have suggested that memantine may improve neurologic and cognitive symptoms of individuals with the neurodegenerative disease fragile X-associated tremor/ataxia syndrome (FXTAS); however, its efficacy and safety in this population have not been assessed in a controlled trial. Results: Ninety-four participants were randomized from 205 screened; of those, 43 and 45 started treatment with memantine (titrated to 10 mg twice daily) and placebo, respectively. Thirty-four participants receiving memantine and 36 receiving placebo completed the 1-year endpoint assessment (n = 70). Intention-to-treat analysis showed no improvement with respect to intention tremor severity (mean [SD] (16.12 [5.43] vs 15.72 [3.93], P = .727) at follow-up. Post hoc analyses of participants with early FXTAS (stage ≤ 3), those with late FXTAS (stage > 3), and those in different age groups (≤ 65 years and > 65 years) also indicated no significant improvement. More frequent mild adverse events were observed in the placebo group, while more frequent moderate adverse events occurred in the memantine group (P = .007).
T
he fragile X mental retardation 1 (FMR1) gene premutation, with 55-200 CGG repeats, is present in about 1/130-260 females and 1/250-810 males in the general population.
1,2 When premutation alleles are maternally transmitted, they may expand into the full mutation range, over 200 CGG repeats. The full mutation silences the gene, resulting in the absence or severe deficiency of the FMR1 protein, which manifests clinically as fragile X syndrome. Until recently, premutation carriers were believed to be unaffected, with the exception of primary ovarian insufficiency, which can occur in up to 20% of female carriers. 3, 4 At the beginning of this millennium, neurologic symptoms were first noted in aging premutation carriers, and elevated levels of FMR1 mRNA were found in premutation blood cells. [5] [6] [7] These discoveries have shifted the paradigm and stimulated an exponential growth of research aimed at understanding the clinical and molecular features associated with the premutation.
Premutation carriers may have autoimmune, endocrine, neurologic, and psychiatric involvement. [8] [9] [10] [11] In late life, they may develop a neurodegenerative disease, fragile X-associated tremor/ataxia syndrome (FXTAS). FXTAS affects approximately 40% of male premutation carriers older than 50 years and up to 16% of female carriers and has also been described in individuals with gray zone alleles (45-54 CGG repeats). [12] [13] [14] [15] Clinical manifestations include intention tremor, ataxia, parkinsonism, peripheral neuropathy, autonomic dysfunction, psychiatric symptoms, and cognitive impairment. [16] [17] [18] [19] FXTAS diagnostic criteria have been proposed. 7, 20 Recently, Apartis et al 19 called for a revision of these criteria. FXTAS progresses in 6 successive stages of physical disability outlined by Bacalman et al 21 : (1) subtle or questionable tremor and/or balance problems; (2) minor tremor and/or balance problems, with minimal interference in activities of daily living (ADLs); (3) moderate tremor and/or balance problems with significant interference in ADLs; (4) severe tremor and/or balance problems, with need to use a cane or walker; (5) daily use of a wheelchair; and (6) bedridden. Affected individuals may experience falls about 6 years after the onset of the motor signs; by 16 
Clinical Points
NMDA antagonists have also been shown to attenuate NMDA-induced impairments in long-term potentiation, a central mechanism in learning and memory. 27, 28 Abnormal glutamate activity has been observed in mouse hippocampal premutation neurons with 170 CGG repeats grown in vitro, which have a reduced expression of vesicular γ-aminobutyric acid (GABA) and glutamate transporters. 29 Memantine is currently approved by the US Food and Drug Administration for the treatment of moderate to severe Alzheimer's disease. A Cochrane database analysis found that memantine had a small beneficial effect at 6 months on cognition, behavior, and the ability to perform ADLs in patients with moderate to severe Alzheimer's disease. 30 Although there is insufficient evidence to support offlabel indications, memantine has also been used for other cognitive disorders including mild Alzheimer's disease, dementia with Lewy bodies, Parkinson's disease dementia, and vascular dementia. 24, [30] [31] [32] [33] Memantine may improve parkinsonism and dyskinesias in patients with Parkinson's disease, as well as neuropsychiatric symptoms in those with Alzheimer's disease. 34, 35 Additionally, memantine has been explored as monotherapy or as an augmenting agent in anxiety disorders, bipolar disorder, opioid dependency, schizophrenia, traumatic brain injury, and neuropathic pain, with mixed results. 36, 37 When used as an add-on therapy in refractory bipolar disorder, memantine has shown modest mood-stabilizing properties and early antidepressant effects. 37, 38 In a year-long randomized controlled trial (RCT) of adults 40 years and older with Down's syndrome with or without dementia, there was no difference between memantine and placebo on cognitive and behavioral measures. 39 However, a smaller RCT 40 showed a moderate benefit on the California Verbal Learning Test (CVLT)-II Free Recall total score in adults ages 18-32 years with Down's syndrome who took memantine for 16 weeks, compared to matched controls.
To date, 1 case report 41 has illustrated improvement in both neurologic and cognitive symptoms of FXTAS in a female carrier treated with memantine. We hypothesized that memantine improves the cognitive, neurologic, and behavioral symptoms of FXTAS and tested this hypothesis with the first double-blind RCT conducted in individuals with FXTAS.
METHOD

Study Design and Participants
The study protocol was approved by the institutional review boards at the University of California 
Randomization
Potential participants were self-referred or physicianreferred to participate in studies of FXTAS. Participants were contacted by telephone or e-mail; those who potentially met eligibility criteria were scheduled for a baseline visit. After investigators determined the FXTAS diagnosis and thus participant eligibility, randomization was done by the UC Davis pharmacy to either placebo or memantine. All study personnel, investigators, and participants were blinded to the treatment assigned until completion of the trial.
Intervention
The study medication consisted of identical tablets containing either memantine or placebo, provided to participants at no cost. The study medication was either obtained at the UC Davis pharmacy after the baseline evaluation or shipped directly to the participant's home. The titration schedule was explained to participants; instructions were also included with the medication. Titration started with 5 mg (1 tablet) once a day for 1 week, increasing to 5 mg twice a day for 1 week, then to 5 mg in the morning and 10 mg in the evening for 1 week and finally to 10 mg twice a day. The study coordinator called participants at 1 month, 3 months, and 6 months to inquire whether they had experienced any adverse events.
Evaluation Protocol
The baseline evaluation protocol consisted of genetic testing, a detailed medical history, a physical examination, a comprehensive neuropsychological test battery, the CATSYS protocol, 42 and a psychiatric assessment, using a customized version of the Structured Clinical Interview for DSM-IV-TR Axis I Disorders (SCID). 43 The FXTAS diagnosis and stage were established by investigators on the basis of previously published criteria. 7, 20, 21 The participants' complete medication lists were verified to exclude any possible interactions with memantine. Participants were asked to keep all other medications unchanged for the duration of the study. Hepatic and renal function tests were obtained and reviewed.
The neuropsychological test battery included the Wechsler Adult Intelligence Scale-Third Edition (WAIS-III), 44 performed at baseline, and the following measures, performed at baseline and 1-year follow-up: the Mini-Mental State Examination 45 ; the Behavioral Dyscontrol Scale (BDS), 46 which measures executive function, as detailed below; the CVLT, 47 a word learning test; the Controlled Oral Word Association Test (COWAT), 48 indicative of verbal fluency and considered a measure of executive functioning; and the Wechsler Memory Scale-Third Edition (WMS-III). 49 The BDS is a 9-item, 27-point instrument that measures executive function as the capacity for behavioral and attentional self-regulation. 46 The BDS has been widely used in studies of premutation carriers. [50] [51] [52] CATSYS is a set of computer-assisted diagnostic instruments that can measure intention tremor, postural tremor, postural sway, manual coordination, and reaction time. 42 CATSYS has been previously used in premutation carriers. 53, 54 The SCID was customized prior to initiating this study to include the modules for mood, anxiety, substance use, somatoform, and adjustment disorders and the screening questions for psychotic symptoms. Additionally, dementia and cognitive disorder not otherwise specified were diagnosed through interview according to the DSM-IV-TR criteria. 55 Participants returned 1 year later and were reevaluated according to the same protocol, with the exception that WAIS-III and SCID were not repeated. The follow-up psychiatric evaluation was a 1-hour interview focused on life stressors and any subjective improvement or decline in participants' cognitive, emotional, and functional status. The medical history and examination included medication review, side effects, and hepatic and renal function tests. After the follow-up assessment was completed, all participants were invited to exit the study and unblinded with regard to treatment status.
Molecular Measures
Genomic DNA was isolated from peripheral blood leukocytes (5 mL of whole blood) using standard methods (Qiagen; Valencia, California). Southern blot analysis, polymerase chain reaction (PCR) analysis, and calculation of the CGG repeat size were performed as described by Tassone et al. 56 
Statistical Analysis
The primary outcomes at 1-year follow-up were the BDS total score and CATSYS intention tremor severity. Thus, tests for primary efficacy were Bonferroni adjusted with a significance level of P < .025 (2-tailed) for n = 70 participants. Our a priori-specified tests were t tests, and these are reported. Groups were also compared, adjusted for baseline measurements, using analysis of covariance (ANCOVA); the results remained the same. All other measures and associated analyses were secondary. Adverse events were summarized by severity, putative causal relation to drug, action taken to address the adverse event, and whether they required treatment. Student t test and Fisher exact test were applied to continuous and categorical variables. Tests were conducted at a significance level of < .05, except for primary efficacy, for which the level was < .025. Analyses were implemented in SAS version 9.2 (SAS Institute; Cary, North Carolina). We aimed to detect a standardized effect size of 0.67 for 94 total participants (47 in each arm) at 90% power at level .025. We note that with 70 participants, the power is 80% to detect the same effect size.
Post Hoc Analyses
Post hoc analyses of younger participants (age ≤ 65 years, n = 33), older participants (age > 65 years, n = 37), those with early FXTAS (stage ≤ 3, n = 50), and those and with late FXTAS (stage > 3, n = 20) were also performed. For post hoc analyses, comparison for treatment effect was based on ANCOVA, adjusted for baseline measurement.
RESULTS
Participant Characteristics
Of the 205 participants assessed for eligibility, 94 (ages 34-80 years) were randomized into 1 of the 2 treatment arms. Randomized participants' demographic characteristics are shown in Table 1 . There were no significant demographic differences between the memantine and placebo groups.
Forty-three participants started treatment with memantine, and 45 started placebo. Seventy participants (34 taking memantine and 36 taking placebo) completed the 1-year follow-up, after the exclusion of 1 participant who had experienced complete loss of physical functioning due to unknown etiology (see Figure 1) .
Primary Outcome Analysis
The primary outcome measures were the BDS total score and CATSYS intention tremor severity. No treatment effects were found for BDS score: the memantine group mean (SD) score was 16.12 (5.43), compared to the placebo group mean of 15.72 (3.93) (P = .727). Similarly, there was no treatment effect with respect to intention tremor, with a memantine group mean severity of 1.05 (0.73) and placebo group mean of 1.89 (2.19) (P = .047) ( Table 2) .
Secondary Outcome Analysis
The secondary outcome measures included CATSYS postural and writing tremor severity and hand and finger tapping maximum frequency (indicating manual coordination). Secondary outcomes also included tests of declarative learning (CVLT), working memory (WMS-III working memory index score), and executive function (COWAT). Again, treatment effects were not observed with respect to any secondary measure (see Table 2 ).
Post Hoc Analyses
In post hoc analyses, we explored whether memantine was effective in subgroups that may potentially benefit from treatment. We considered subgroups of (1) younger participants (age ≤ 65 years, n = 33), (2) those with early FXTAS (stage ≤ 3, n = 50), (3) older participants (age > 65 years, n = 37), and (4) those with late FXTAS (stage > 3, n = 20). No efficacy was found for post hoc analyses of primary or secondary outcome measures described above (results not shown).
Safety
There were 99 adverse events reported for 48 participants. Table 3 summarizes adverse event categories. No significant differences between memantine and placebo were found for causal relation to drug, action taken to address the adverse events, or whether treatment was necessary. However, adverse event severity was significantly different between memantine and placebo: adverse events were more frequently mild in the placebo group (55.81%; 24/43 events) compared to the memantine group (25.00%; 14/56 events) and more frequently moderate in the memantine group (41.07%; 23/56 events) than in the placebo group (18.60%; 8/43 events) (P = .007). 
Additional Considerations
We examined changes in psychotropic medications made during the study period that could have affected the participants' cognitive status. Participants were asked to keep all other medications unchanged while in the study; however, in some cases, treating physicians made adjustments on the basis of participants' clinical status. We examined changes in use of benzodiazepines, antidepressants, and cholinesterase inhibitors during the study period. Table 4 provides a detailed description of these medication changes.
DISCUSSION
This is the first double-blind RCT in individuals with FXTAS. Memantine, an NMDA receptor antagonist, was selected due to its benefit on cognitive and behavioral symptoms of Alzheimer's disease, off-label use for parkinsonism and several psychiatric disorders, and previous anecdotal reports of improvement of FXTAS symptoms in a female carrier. At 1 year, memantine showed no benefit over placebo on the primary outcome measures of intention tremor severity and executive function, and there were no significant differences on the secondary outcome motor and cognitive measures. Post hoc analyses on the primary and secondary measures in participants with early FXTAS (stage ≤ 3), those with late FXTAS (stage > 3), and those in different age groups (≤ 65 years and > 65 years) also yielded no differences.
To date, memantine RCTs have been of variable durations, ranging from 6 weeks to 1 year, with a small benefit noted on 1 switch from olanzapine to aripiprazole a Includes amitriptyline, aripiprazole, bupropion, gabapentin, lamotrigine, methylphenidate, mirtazapine, modafinil, olanzapine, pramipexole, quetiapine, risperidone, and topiramate. Abbreviations: SNRI = serotonin-norepinephrine reuptake inhibitor, SSRI = selective serotonin reuptake inhibitor.
cognition, behavior, and ADLs at 6 months in Alzheimer's disease. 26, 57, 58 We chose 1 year as endpoint for the present study. FXTAS progresses over time; thus, 1 year was thought to be an adequate interval to measure outcomes, since shorter times could capture transient improvements. Due to the rigorous study design and inclusion/exclusion criteria, only 94 of the 205 carriers screened were randomized. Nevertheless, the final sample size (n = 70) was sufficient to observe changes of a moderately large effect size with 80% power. It should be noted that this study, similar to other clinical trials, does not rule out the possibility that some individuals with FXTAS may respond to memantine treatment. 41 Memantine showed no benefit in a recent RCT in patients with frontotemporal lobar degeneration, highlighting its limited success in neurodegenerative diseases besides Alzheimer's disease. 59 Similarly, there is insufficient evidence to date to recommend the use of memantine in Parkinson's disease dementia. 33 Even though dysfunction of the glutamate and GABA systems appears to play a role in the neurodegenerative changes of FXTAS, no single neurotransmitter has been clearly implicated. 29 The pathophysiologic mechanism in FXTAS is complex, involving elevated levels of FMR1 mRNA, dysregulation and sequestration of intracellular proteins, altered miRNA processing, mitochondrial dysfunction, and defective iron and zinc homeostasis. [60] [61] [62] Mitochondrial dysfunction is believed to be central to neurodegenerative processes and has recently been described in another triplet repeat disorder, Huntington's disease. 63, 64 Targeted treatments addressing the mitochondrial dysfunction, such as creatine and coenzyme Q10, have been studied in Parkinson's disease and Huntington's disease and might provide a good diseasemodifying template for FXTAS. 65 In the present study, the CATSYS was used to measure tremor, postural sway, and reaction time. The gold standard in assessment of motor parkinsonian features is the Unified Parkinson's Disease Rating Scale (UPDRS), which is widely used and has good reliability and validity. 66 CATSYS was selected as it had been previously used in premutation carriers; also, a recent study showed CATSYS measurements to be associated with clinician-rated UPDRS items assessing tremor and bradykinesia. 53, 54, 67 Future studies could include UPDRS in the protocol, to complement the CATSYS.
Psychiatric symptoms, in particular depression and anxiety, are common in premutation carriers. 8, 10, 68 We examined changes in psychotropic medications during the study in order to make sure these did not confound our results. For example, benzodiazepines may help mitigate tremor and anxiety but have well-known deleterious effects on cognition. By discontinuing benzodiazepines, the participants' cognition might have improved; however, the severity of their tremor might have increased. Also, the titration of selective serotonin reuptake inhibitors or serotonin-norepinephrine reuptake inhibitors might have improved cognitive functioning by ameliorating the deficits associated with anxiety and depression.
69, 70 However, in our study, few medications were changed, with no differences across the 2 groups. While targeted disease-modifying treatments for FXTAS are still awaiting development, symptomatic approaches have been used for its neurologic, cognitive, and psychiatric symptoms. 17, [71] [72] [73] The cholinesterase inhibitor donepezil has been used as a cognitive enhancer with good results in 1 case report. 74 Previous studies showed that adding memantine to ongoing donepezil treatment in patients with moderate to severe Alzheimer's disease resulted in significantly better outcomes than placebo on measures of cognition, ADLs, and behavior. 75 A similar rationale may inform future studies in FXTAS, using the memantine-donepezil combination. However, the efficacy of cholinesterase inhibitors has not yet been established in this population; this step should be undertaken first, in order to avoid exposing patients to unnecessary side effects.
CONCLUSION
This was the first RCT in individuals with FXTAS; no significant benefit was observed for the cognitive enhancer memantine compared to placebo at 1 year. Limitations of this study included the moderate sample size, with fewer individuals in late FXTAS stages (n = 20); the use of only the CATSYS to quantify tremor; and psychotropic medication changes, which are difficult to avoid in this population with multiple psychiatric comorbidities. Future studies exploring targeted treatments that address the molecular genetic aberrations, mitochondrial dysfunction, and defective iron and zinc homeostasis are needed. In the meantime, symptomatic treatments will continue to offer partial comfort to patients with FXTAS.
